MedPath

Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Conditions
Diffuse Parenchymal Lung Disease
Registration Number
NCT04392726
Lead Sponsor
Sheba Medical Center
Brief Summary

The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims:

1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping.

2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  1. suspected or known DPLD
  2. referred to DPLD observation
Exclusion Criteria
  1. other lung related diseases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD.during the procedure/surgery

The diagnostic performance will be evaluated according to the biopsy results

The primary outcome measure of this study is to determine the prognostic performance of ULDCT in the follow up of DPLD.during the procedure/surgery

The diagnostic performance will be evaluated according to the biopsy results

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sheba Medical Center

🇮🇱

Ramat Gan, Israel

© Copyright 2025. All Rights Reserved by MedPath